

261 Mountain View Dr Colchester, VT 05446 License #: TLAB0030 802-767-7256 info@onwardanalytics.biz

0	Client Name: Last Minute Farm, LLC				
	License Number: SCLT0047 & MANU0062				

I	Sample	١D·	VT5974
	Sample	שו.	VIJ9/4

Sample Name: Purple Marmalade
Sample Lot: SCLT0047-002-005
Sample Matrix: Flower
Date Received: 12/18/2023
Date Reported: 12/28/2023
Date Tested: 12/27/2023

Total Terpenes (%) : 2.0372

Dominant Terpenes (%)					
beta-caryophyllene	0.7305				
Limonene	0.4394				
alpha-Humulene	0.2142				
Linalool	0.2041				
alpha-Bisabolol	0.1381				

Certificate of Analysis



Terpenes

Standard terpene analysis utilizing Gas Chromatography - Mass Spectrometry (GC-MS; SOP-069-0A) | Test ID: #17219

etallata terpelle allafjele at	inzing oue en en allegiap.	.)					
Analyte	Result (%)	Result (mg/g)	LOD (mg/g)	LOQ (mg/g)			
3-Carene	ND	ND	0.000002	0.002			
alpha-Bisabolol	0.1381	1.381	0.000003	0.002			
alpha-Humulene	0.2142	2.142	0.000002	0.002			
alpha-Pinene	0.0376	0.376	0.000001	0.002			
alpha-Terpinene	ND	ND	0.000001	0.002			
alpha-Terpinolene	< LOQ	< LOQ	0.000004	0.002			
beta-caryophyllene	0.7305	7.305	0.000004	0.002			
beta-Pinene	0.0707	0.707	0.000002	0.002			
Camphene	0.0243	0.243	0.000001	0.002			
Caryophyllene Oxide	0.0479	0.479	0.000011	0.002			
Eucalyptol	ND	ND	0.000002	0.002			
gamma-Terpinene	ND	ND	0.000002	0.002			
Geraniol	ND	ND	0.000008	0.002			
Guaiol	ND	ND	0.00007	0.002			
Isopulegol	ND	ND	0.000005	0.002			
Isopropyl Toluene	ND	ND	0.000003	0.002			
Limonene	0.4394	4.394	0.000002	0.002			
Linalool	0.2041	2.041	0.000003	0.002			
Nerolidol	0.0569	0.569	0.00007	0.002			
Myrcene	0.0735	0.735	0.00003	0.002			
Ocimene	ND	ND	0.000002	0.002			
Total Terpenes	2.0372	20.372					

Callie Chapman Lab Director 12/28/2023

In performing the services, Onward Analytics, ("OA") shall exercise a degree of skill and care ordinarily exercised by a reasonably prudent laboratory professional under similar circumstances. Except as set forth in the preceding sentence, client acknowledges and agrees that: (a) the services may require OA to make judgements based upon limited data rather than upon scientific certainties; (b) OA's approach, recommendations, and associated cost estimates, if any, are based on industry practices and averages; (c) OA renders its opinions with respect to observations made and data available at the time of testing; (d) ultimate outcomes could be inconsistent with OA's conclusions, results and projections; and (e) there may be additional reports relating to the site (whether prepared by OA or other parties), and reliance upon any OA report without reference to any such other reports is done at client's sole risk.

